359 related articles for article (PubMed ID: 10686191)
1. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.
Albano C; Felberbaum RE; Smitz J; Riethmüller-Winzen H; Engel J; Diedrich K; Devroey P
Hum Reprod; 2000 Mar; 15(3):526-31. PubMed ID: 10686191
[TBL] [Abstract][Full Text] [Related]
2. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
[TBL] [Abstract][Full Text] [Related]
3. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction.
Ludwig M; Felberbaum RE; Devroey P; Albano C; Riethmüller-Winzen H; Schüler A; Engel W; Diedrich K
Arch Gynecol Obstet; 2000 Jul; 264(1):29-32. PubMed ID: 10985616
[TBL] [Abstract][Full Text] [Related]
4. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
Borm G; Mannaerts B
Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
[TBL] [Abstract][Full Text] [Related]
5. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study.
Felberbaum RE; Albano C; Ludwig M; Riethmüller-Winzen H; Grigat M; Devroey P; Diedrich K
Hum Reprod; 2000 May; 15(5):1015-20. PubMed ID: 10783344
[TBL] [Abstract][Full Text] [Related]
6. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
7. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).
Olivennes F; Belaisch-Allart J; Emperaire JC; Dechaud H; Alvarez S; Moreau L; Nicollet B; Zorn JR; Bouchard P; Frydman R
Fertil Steril; 2000 Feb; 73(2):314-20. PubMed ID: 10685535
[TBL] [Abstract][Full Text] [Related]
8. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.
Seow KM; Lin YH; Huang LW; Hsieh BC; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
Gynecol Endocrinol; 2007 Jun; 23(6):338-42. PubMed ID: 17616858
[TBL] [Abstract][Full Text] [Related]
9. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles.
Albano C; Smitz J; Tournaye H; Riethmüller-Winzen H; Van Steirteghem A; Devroey P
Hum Reprod; 1999 Jun; 14(6):1426-30. PubMed ID: 10357952
[TBL] [Abstract][Full Text] [Related]
10. Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?
Lin Y; Kahn JA; Hillensjö T
Hum Reprod; 1999 Apr; 14(4):885-8. PubMed ID: 10221213
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection.
Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N
Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477
[TBL] [Abstract][Full Text] [Related]
12. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
13. [Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles].
Zhang J; Zhou X; Chen Y; Zhang Q; Li Y; Zhe J; Chen X; Chen S
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Oct; 39(10):1207-1212. PubMed ID: 31801718
[TBL] [Abstract][Full Text] [Related]
14. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
15. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix.
Tavaniotou A; Albano C; Smitz J; Devroey P
Hum Reprod; 2001 Apr; 16(4):663-7. PubMed ID: 11278214
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial.
Lee TH; Lin YH; Seow KM; Hwang JL; Tzeng CR; Yang YS
Fertil Steril; 2008 Jul; 90(1):113-20. PubMed ID: 18054932
[TBL] [Abstract][Full Text] [Related]
17. Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol--a randomized study.
Lin YH; Hwang JL; Seow KM; Huang LW; Hsieh BC; Tzeng CR
Gynecol Endocrinol; 2006 Jun; 22(6):297-302. PubMed ID: 16785154
[TBL] [Abstract][Full Text] [Related]
18. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
[TBL] [Abstract][Full Text] [Related]
19. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
[TBL] [Abstract][Full Text] [Related]
20. The impact of LH serum concentration on the clinical outcome of IVF cycles in patients receiving two regimens of clomiphene citrate/gonadotrophin/0.25 mg cetrorelix.
Tavaniotou A; Albano C; Van Steirteghem A; Devroey P
Reprod Biomed Online; 2003 Jun; 6(4):421-6. PubMed ID: 12831586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
